Appli OneTouch Reveal® vs epocrates: Drug Info & Pill ID
Revenue, downloads, ratings and category context for two iOS apps. Figures are estimates and should be read as ranges, not exact totals.
| Metric | Appli OneTouch Reveal® | epocrates: Drug Info & Pill ID | Readout |
|---|---|---|---|
| Estimated revenue / mo | $*** - opens with trial | $*** - opens with trial | epocrates: Drug Info & Pill ID |
| Revenue band | $*** - opens with trial | $*** - opens with trial | Use range + confidence |
| Estimated downloads / mo | $*** - opens with trial | $*** - opens with trial | Appli OneTouch Reveal® |
| Download band | $*** - opens with trial | $*** - opens with trial | Use range + confidence |
| Rating | - | 4.44 | epocrates: Drug Info & Pill ID |
| Rating count | - | 7.1k | epocrates: Drug Info & Pill ID |
| Tracked keywords | — | 1 | epocrates: Drug Info & Pill ID |
| Category | Medical | Medical | Same market |
Which app is bigger?
Appli OneTouch Reveal® and epocrates: Drug Info & Pill ID are compared inside Medical with monthly revenue, downloads, rating, review volume, keyword footprint, category placement and range context. Appli OneTouch Reveal® leads on monthly downloads in the current readout, and epocrates: Drug Info & Pill ID wins the revenue readout (the exact figures open with the paid plan), Appli OneTouch Reveal® wins demand, epocrates: Drug Info & Pill ID has deeper review volume, and epocrates: Drug Info & Pill ID has the larger tracked keyword footprint. The better app depends on the job: choose the revenue leader when you need monetization proof, choose the download leader when reach matters, and choose the higher-rated or deeper-reviewed app when market trust is the constraint. Read both ranges rather than only the midpoint, then open the category hub and related collections to see whether this pair is an outlier or a normal category pattern.